Heart failure & cardiomyopathiesRandomised controlled trial
Avoiding Treatment in Hospital With Subcutaneous Furosemide for Worsening Heart Failure
- Randomised controlled trial
- open-label
- pilot
- 2:1 randomisation
Authors' conclusion
SC furosemide augmented weight loss in patients with HF and worsening congestion. The composite primary endpoint was not statistically significant in this pilot investigation.
Study context
- Population
- Outpatients with chronic heart failure (HF) and worsening congestion
- Participants
- 34 vs 17
- Comparison
- Subcutaneous (SC) furosemide vs usual care
- SC furosemiden = 34
- Usual care (UC)n = 17reference
- Primary endpoint
- Win ratio of hierarchical composite of:
- CV death
- HF events
- Change in NT-proBNP
- Follow-up
- 30 days
Primary result
As reported in the abstract
Win ratio (CV death, HF events, NT-proBNP change)
Win ratio
1.11
95% CI 0.48–2.50
P = 0.806
SC furosemide vs UC
win ratio 1.11 (95% CI 0.48–2.50); P = 0.806
Secondary outcomes
| Outcome | difference in least square mean change (kg) (95% CI) | P value | |
|---|---|---|---|
| Body weight change · day 3 | −2.02 (−3.9 to −0.14) | P = 0.035 | |
| −4−202Difference, kg (linear scale) |
| Outcome | least square mean difference (95% CI) | P value | |
|---|---|---|---|
| KCCQ-12 Overall Summary Score · trend | 9.15 (1.95–20.3) | P = 0.106 | |
| −100102030Difference (linear scale) |
| Outcome | Estimate | P value |
|---|---|---|
| 7-point dyspnea score · favoring SC furosemide | P = 0.017 | |
| 6-minute walk test · favoring SC furosemide | P = 0.032 |
Safety
| Outcome | SC furosemide | UC |
|---|---|---|
| Most common related AE: mild infusion site pain | 11.8% | Not reported in the abstract |
Original publication
Avoiding Treatment in Hospital With Subcutaneous Furosemide for Worsening Heart Failure. JACC Heart Fail. Published 11 September 2024. doi:10.1016/j.jchf.2024.07.015
Summarised from the published abstract; every number is checked against it